secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001437749-23-008498
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva reports FY2022 net loss of $24.3M; cash runway through Q3 2023; Phase 3 topline data expected mid-2023
--------------------------------------------------------------------------------

- Net loss of $24.3M ($1.25 per share) vs $8.5M ($0.58 per share) in FY2021.
- Cash and equivalents $18.5M as of Dec 31, 2022, down from $29.7M; cash expected to fund operations through Q3 2023.
- Over 50% of ~400 patients enrolled in pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia; topline data expected mid-2023.
- Completed majority of prelaunch studies for NDA submission; positive drug-drug interaction data reported.
- May initiate Phase 2a studies in bipolar disorder, MDD, ADHD in H2 2023 subject to additional financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923008498/0001437749-23-008498-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774923008498/rvph20230327_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-008498

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer